We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 25, 2023

Association of PSA Decline With Clinical Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer Receiving Apalutamide Plus ADT

Annals of Oncology


Additional Info

Annals of Oncology
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer
Ann. Oncol 2023 Feb 27;[EPub Ahead of Print], S Chowdhury, A Bjartell, N Agarwal, BH Chung, RW Given, AJ Pereira de Santana Gomes, AS Merseburger, M Özgüroğlu, ÁJ Soto, H Uemura, D Ye, SD Brookman-May, A Londhe, A Bhaumik, SD Mundle, JS Larsen, SA McCarthy, KN Chi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading